BLUE240719P1500
- 0.35
- 0.000.00%
bluebird bio Newsroom
BofA Securities Maintains Bluebird Bio(BLUE.US) With Buy Rating
BofA Securities analyst Jason Gerberry maintains $bluebird bio(BLUE.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 44.4% and a total average return of -0.6%
Bluebird Bio (BLUE) Gets a Buy From Bank of America Securities
Bluebird Bio Reports Inducement Grant to CFO James Sterling Under Nasdaq Listing Rule 5635(c)(4)
bluebird bio, Inc. (NASDAQ:BLUE) today announced that the Compensation Committee of the Company's Board of Directors approved an inducement grant of stock options to purchase a total of 300,000 shares of common stock to
2Flo Ventures Announces Addition of Renowned Life Sciences Executive Charlotte Jones-Burton, MD, MS as a Partner
2Flo Ventures, an emerging venture capital firm and startup studio focused on the discovery, development, and commercialization of healthcare...
BioLineRx Stock Jumps 14% on St. Jude Clinical Trial for Mitoxafortide
Bluebird Bio Announces CFO Transition and Compensation Details
Bluebird Bio Says Continuing To Work Expeditiously To Complete Delayed Filings
On March 26, 2024, bluebird announced that it will restate its consolidated financial statements for the first three quarters and full-year 2022, as well as the first three quarters of 2023. As a resu
Express News | Bluebird bio Inc - Appointed Chief Financial Officer (CFO), Effective June 10, 2024
Express News | Bluebird bio Appoints O. James Sterling as Chief Financial Officer
Bluebird Bio Appoints O. James Sterling As Chief Financial Officer >BLUE
Bluebird Bio Appoints O. James Sterling As Chief Financial Officer >BLUE
BLUE Vs. CRSP: Why Are These Stocks Moving in Opposite Directions?
Is Bluebird Bio Stock a Buy?
Express News | Bluebird bio: Sees Significant Changes to Results of Operations for Qtr Ended March 31, 2024 Compared to Corresponding Period Ended in 2023
Express News | Bluebird bio Inc Files for Non-Timely 10-Q With U.S. SEC
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Bluebird Bio (BLUE) and Nuvalent (NUVL)
Bluebird Bio, Inc. (BLUE) Q1 2024 Earnings Call Transcript
bluebird bio, Inc. (BLUE) Q1 2024 Earnings Call Transcript
Bluebird Bio, Inc. (NASDAQ:BLUE) Q1 2024 Earnings Call Transcript
Bluebird Bio (BLUE) Receives a Hold From RBC Capital
Analysts Offer Insights on Healthcare Companies: Health Catalyst (HCAT), Bluebird Bio (BLUE) and Viatris (VTRS)
William Blair Sticks to Its Hold Rating for Bluebird Bio (BLUE)